Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,750
-900 (-4.83%)
Apr 28, 2026, 3:30 PM KST
18.57%
Market Cap 434.87B
Revenue (ttm) 3.76B
Net Income (ttm) -8.99B
Shares Out 24.50M
EPS (ttm) -374.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 105,250
Average Volume 97,422
Open 18,460
Previous Close 18,650
Day's Range 17,750 - 18,640
52-Week Range 11,390 - 33,300
Beta 0.24
RSI 46.72
Earnings Date Apr 2, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2025, Genomictree's revenue was 3.76 billion, an increase of 59.17% compared to the previous year's 2.36 billion. Losses were -8.99 billion, -12.27% less than in 2024.

Financial Statements

News

There is no news available yet.